Please use this identifier to cite or link to this item:
|Title:||In Vitro Metabolic Fate of the Synthetic Cannabinoid Receptor Agonists QMPSB and QMPCB (SGT-11) Including Isozyme Mapping and Esterase Activity|
|Author(s):||Richter, Matthias J.|
Gampfer, Tanja M.
Brandt, Simon D.
Meyer, Markus R.
|Year of Publication:||2021|
|Free key words:||QMPSB|
synthetic cannabinoid receptor agonists
|DDC notations:||610 Medicine and health|
|Publikation type:||Journal Article|
|Abstract:||Quinolin-8-yl 4-methyl-3-(piperidine-1-sulfonyl)benzoate (QMPSB) and quinolin-8-yl 4- methyl-3-(piperidine-1-carbonyl)benzoate (QMPCB, SGT-11) are synthetic cannabinoid receptor agonists (SCRAs). Knowing their metabolic fate is crucial for the identification of toxicological screening targets and to predict possible drug interactions. The presented study aimed to identify the in vitro phase I/II metabolites of QMPSB and QMPCB and to study the contribution of different monooxygenases and human carboxylesterases by using pooled human liver S9 fraction (pHLS9), recombinant human monooxygenases, three recombinant human carboxylesterases, and pooled human liver microsomes. Analyses were carried out by liquid chromatography high-resolution tandem mass spectrometry. QMPSB and QMPCB showed ester hydrolysis, and hydroxy and carboxylic acid products were detected in both cases. Mono/dihydroxy metabolites were formed, as were corresponding glucuronides and sulfates. Most of the metabolites could be detected in positive ionization mode with the exception of some QMPSB metabolites, which could only be found in negative mode. Monooxygenase activity screening revealed that CYP2B6/CYP2C8/CYP2C9/CYP2C19/CYP3A4/CYP3A5 were involved in hydroxylations. Esterase screening showed the involvement of all investigated isoforms. Additionally, extensive non-enzymatic ester hydrolysis was observed. Considering the results of the in vitro experiments, inclusion of the ester hydrolysis products and their glucuronides and monohydroxy metabolites into toxicological screening procedures is recommended.|
|DOI of the first publication:||10.3390/metabo11080509|
|Link to this record:||urn:nbn:de:bsz:291--ds-345882|
|Date of registration:||27-Aug-2021|
|Description of the related object:||Supplementary Materials|
|Faculty:||M - Medizinische Fakultät|
|Department:||M - Experimentelle und Klinische Pharmakologie und Toxikologie|
|Professorship:||M - Prof. Dr. Markus Meyer|
|Collections:||SciDok - Der Wissenschaftsserver der Universität des Saarlandes|
Files for this record:
|metabolites-11-00509-v3.pdf||3,24 MB||Adobe PDF||View/Open|
This item is licensed under a Creative Commons License